Antimicrobial Susceptibility Testing Instrument Sales

Antimicrobial Susceptibility Testing Instrument Sales Market Outlook

The global Antimicrobial Susceptibility Testing Instrument market is projected to reach a significant valuation of approximately USD 4.5 billion by 2035, with a compound annual growth rate (CAGR) of around 7.8% from 2025 to 2035. The increasing prevalence of infectious diseases, particularly those caused by antibiotic-resistant bacteria, is driving the demand for effective testing solutions. Moreover, advancements in technology, such as the development of automated systems and rapid testing methodologies, are expected to further propel market growth. The urgency for accurate antimicrobial susceptibility tests in clinical diagnostics is heightened by the rising concerns regarding public health and the need for precise treatment regimens. Additionally, the growing emphasis on personalized medicine and the integration of artificial intelligence in diagnostics are anticipated to create new opportunities for market expansion.

Growth Factor of the Market

One of the primary growth factors for the Antimicrobial Susceptibility Testing Instrument market is the surge in antibiotic resistance, which presents significant challenges in treating infectious diseases effectively. This resistance necessitates the need for accurate and timely antimicrobial susceptibility testing to guide treatment decisions. Furthermore, the rise in chronic diseases and the resultant increase in hospital admissions amplify the demand for these testing instruments. Innovative technologies in diagnostics, such as molecular testing and rapid identification systems, are also contributing to market expansion, as they provide timely results critical for patient management. Moreover, supportive government initiatives aimed at combating antimicrobial resistance by promoting research and development of novel antimicrobial agents are expected to boost market growth. Lastly, the increasing investment in healthcare infrastructure, particularly in developing regions, is anticipated to enhance accessibility to advanced testing modalities.

Key Highlights of the Market

• The market is expected to grow significantly, driven by rising antibiotic resistance and the demand for rapid testing solutions.
• Automated AST instruments are gaining traction due to their efficiency and accuracy in delivering test results.
• Clinical diagnostics remain the largest application segment, emphasizing the importance of testing in patient care.
• North America is anticipated to hold the largest market share, followed closely by Europe, due to advanced healthcare facilities.
• Significant investments in R&D by pharmaceutical companies are paving the way for innovative testing methodologies.

By Product Type

Automated AST Instruments:

Automated Antimicrobial Susceptibility Testing (AST) instruments are revolutionizing the healthcare landscape by providing rapid and precise results that are essential in clinical settings. These instruments leverage advanced technology to streamline the testing process, significantly reducing the time required to obtain susceptibility profiles of pathogens. With the growing burden of antibiotic-resistant infections, the demand for automated systems is on the rise, as they not only enhance the throughput of testing but also minimize human error. The integration of automation in AST allows for increased laboratory efficiency, enabling healthcare professionals to make informed decisions faster. Consequently, the market for automated AST instruments is expected to witness robust growth in the coming years, driven by an increasing need for efficient diagnostic solutions and improved patient outcomes.

Manual AST Instruments:

Manual AST instruments continue to play a vital role in laboratories that require flexibility and a hands-on approach to antimicrobial testing. Despite the rise of automation, many laboratories rely on manual methods to perform susceptibility tests, particularly in settings where resources are limited or where specific testing conditions are necessary. Manual AST is often perceived as a cost-effective option, allowing diagnostic laboratories to maintain a high level of accuracy without significant capital investment in equipment. However, the manual process requires skilled personnel and can be time-consuming. While the market for manual AST instruments is facing challenges due to automation, it still holds a substantial share, especially in developing regions where automated solutions may not yet be widely accessible.

Semi-Automated AST Instruments:

Semi-automated AST instruments bridge the gap between manual and fully automated systems, offering a hybrid approach that combines the efficiency of automation with the flexibility of manual testing. These instruments allow for the automation of certain steps in the testing process while still requiring some level of user intervention. This adaptability makes semi-automated systems appealing to laboratories that seek to enhance their testing capabilities without fully committing to automation. They provide a balance between speed and accuracy, making them suitable for a variety of applications, including clinical diagnostics and research settings. As the demand for efficient testing solutions grows, the segment of semi-automated AST instruments is expected to expand, driven by the need for versatile and cost-effective solutions in laboratories.

By Application

Clinical Diagnostics:

Clinical diagnostics represent the largest application segment within the Antimicrobial Susceptibility Testing Instrument market. The rising incidence of infectious diseases, coupled with the increasing prevalence of antibiotic-resistant pathogens, underscores the critical importance of accurate susceptibility testing in guiding effective treatment regimens. Healthcare providers rely on timely and precise test results to make informed decisions regarding antibiotic therapies, ultimately improving patient outcomes. Additionally, the growing focus on personalized medicine, which tailors treatment to individual patient profiles, further drives demand for sophisticated testing methods in clinical settings. As healthcare systems continue to prioritize patient safety and effective infection control measures, the clinical diagnostics application is expected to experience substantial growth in the coming years.

Drug Discovery and Development:

The application of antimicrobial susceptibility testing in drug discovery and development is gaining increased attention as pharmaceutical companies strive to develop novel antimicrobial agents. With the alarming rise of antibiotic resistance, understanding how new compounds perform against resistant strains is crucial for effective drug development. Testing instruments play a significant role in screening potential drug candidates and determining their efficacy against a range of pathogens. This application not only contributes to the identification of promising therapeutic options but also aids in the regulatory approval process for new drugs. As the pharmaceutical industry invests heavily in the development of innovative therapies to combat resistant infections, the drug discovery and development application segment is poised for significant growth, fueled by advancements in testing methodologies and technology.

Epidemiology:

Epidemiological studies are essential for understanding the patterns, causes, and effects of health and disease conditions in specific populations. The use of antimicrobial susceptibility testing instruments in epidemiology plays a critical role in tracking the spread of resistant organisms and informing public health strategies. By analyzing susceptibility data, researchers and public health officials can identify trends in resistance patterns, assess the effectiveness of treatment protocols, and develop targeted interventions to combat the spread of resistant pathogens. The increasing emphasis on surveillance and research activities to monitor resistance trends is driving the demand for susceptibility testing instruments in this application. As public health initiatives focus on mitigating the impact of antibiotic resistance, the epidemiology application segment is expected to witness significant growth in conjunction with ongoing research efforts.

By End User

Hospitals:

Hospitals are one of the primary end users of antimicrobial susceptibility testing instruments, given their critical need for accurate and timely diagnostic solutions to manage infections effectively. In a hospital setting, quick identification of pathogens and their susceptibility to antibiotics is essential for ensuring appropriate treatment and minimizing the risk of complications. The increasing number of hospital-acquired infections and the growing prevalence of multidrug-resistant organisms have heightened the demand for robust testing capabilities within healthcare facilities. Hospitals are increasingly adopting advanced testing methodologies to enhance their infection control measures and improve patient safety. As a result, the hospital segment is poised for substantial growth, fueled by the ongoing efforts to combat infections and enhance clinical outcomes.

Diagnostic Laboratories:

Diagnostic laboratories play a pivotal role in the antimicrobial susceptibility testing landscape, serving as the central hubs where a large volume of testing is conducted. These laboratories are equipped with advanced technologies and skilled personnel to perform a wide range of susceptibility tests on various microorganisms. With the increasing demand for accurate diagnostics in both clinical and research settings, diagnostic laboratories are continuously investing in new testing instruments and methodologies to improve their service offerings. The rapid turnaround times required for testing results further emphasize the need for efficiency and accuracy in these settings. As the healthcare sector continues to evolve, diagnostic laboratories are expected to experience significant growth, driven by the need for comprehensive testing solutions and the urgency of addressing antimicrobial resistance.

Pharmaceutical & Biotechnology Companies:

Pharmaceutical and biotechnology companies are increasingly utilizing antimicrobial susceptibility testing instruments in their research and development processes to discover and develop new antimicrobial agents. The rise of antibiotic resistance has created an urgent need for innovative therapies, prompting these companies to invest heavily in research efforts aimed at combating resistant infections. Testing instruments provide critical data on the efficacy of potential drug candidates, allowing researchers to optimize formulations and identify the most promising therapies for further development. Moreover, regulatory requirements for antimicrobial products necessitate the use of reliable testing methodologies to demonstrate efficacy during the approval process. As the pharmaceutical industry continues to prioritize the development of new antimicrobials, the segment of pharmaceutical and biotechnology companies is expected to witness substantial growth in the coming years.

Research Institutes:

Research institutes are key players in the antimicrobial susceptibility testing market, as they conduct vital studies aimed at understanding drug resistance mechanisms and the effectiveness of various antimicrobial agents. These institutions are often at the forefront of innovation, utilizing advanced testing technologies to explore new approaches to combat antibiotic resistance. Research institutes collaborate with pharmaceutical companies, universities, and public health organizations to generate data that informs treatment protocols and public health policies. The growing focus on research initiatives to address the global challenge of antimicrobial resistance underscores the significant role of these institutes in the market. As funding for research continues to increase, the demand for susceptibility testing instruments within research settings is anticipated to grow correspondingly.

By Method

Disk Diffusion:

Disk diffusion is a widely used method for antimicrobial susceptibility testing, renowned for its simplicity and cost-effectiveness. In this method, antibiotic-impregnated paper disks are placed on an agar plate inoculated with the pathogen of interest, allowing for the assessment of bacterial growth inhibition. The zone of inhibition around each disk indicates the susceptibility or resistance of the organism to the antibiotic. Despite the emergence of more advanced techniques, disk diffusion remains a staple in many laboratories due to its straightforward procedure and the ability to test multiple antibiotics simultaneously. As a result, the disk diffusion method continues to hold a significant share of the susceptibility testing market, particularly in settings where resources are limited, and reliable results are paramount.

Broth Dilution:

The broth dilution method is another standard approach for antimicrobial susceptibility testing, characterized by its quantitative assessment of bacterial growth in the presence of varying concentrations of antibiotics. This method allows for the determination of the Minimum Inhibitory Concentration (MIC), which is the lowest concentration of an antibiotic that inhibits visible bacterial growth. Broth dilution is highly regarded for its accuracy and reproducibility, making it a preferred choice in many clinical laboratories and research settings. As the complexity of infections and antibiotic resistance patterns continues to evolve, the broth dilution method is expected to maintain its relevance in the market, especially in cases requiring precise quantification of drug efficacy.

E-test:

The E-test (gradient diffusion method) combines elements of both disk diffusion and broth dilution techniques to provide a convenient and accurate means of determining antimicrobial susceptibility. This method utilizes strips coated with a gradient of antibiotics, allowing for a precise measurement of the MIC based on the point where the bacterial growth intersects the strip. The E-test is particularly favored for its ease of use and the ability to test a variety of antibiotics simultaneously. Its versatility makes it suitable for both clinical and research applications, as it allows for the rapid identification of effective treatment options against resistant pathogens. Given the growing emphasis on accurate susceptibility testing, the E-test method is anticipated to gain traction in the market, as laboratories seek efficient and reliable solutions for their diagnostic needs.

Automated Systems:

Automated systems for antimicrobial susceptibility testing are transforming the testing landscape by providing high-throughput capabilities, efficiency, and consistency in results. These systems employ advanced technologies to automate various stages of the testing process, significantly reducing the time taken to obtain susceptibility profiles. The integration of robotics, software algorithms, and data analysis tools facilitates rapid identification of pathogens and their resistance mechanisms. Automated systems are particularly valuable in busy clinical laboratories where rapid turnaround times are critical for patient management. As healthcare providers increasingly prioritize efficiency and accuracy, the demand for automated AST systems is expected to rise, further driving growth in the antimicrobial susceptibility testing instrument market.

By Region

The Antimicrobial Susceptibility Testing Instrument market exhibits varying trends across different regions, driven by factors such as healthcare infrastructure, regulatory environments, and the prevalence of infectious diseases. North America, particularly the United States, holds the largest market share in this sector, accounting for approximately 40% of the global market due to its advanced healthcare system, high prevalence of antibiotic resistance, and significant investments in research and development. The region's commitment to combating antimicrobial resistance through public health initiatives and the integration of advanced testing technologies further strengthens its market position. Additionally, the projected CAGR for North America is around 8.5%, indicating a robust growth trajectory fueled by ongoing innovation and demand for efficient diagnostic solutions.

Europe stands as another prominent region in the antimicrobial susceptibility testing market, holding approximately 30% of the market share. The region is characterized by a strong emphasis on public health policies aimed at addressing antibiotic resistance and promoting responsible antibiotic use. European countries are increasingly adopting advanced testing methodologies to ensure accurate diagnostics and effective treatment protocols. Furthermore, the presence of key players and research institutions in Europe enhances the region's capacity for innovation and development of new testing technologies. The CAGR for the European market is estimated to be around 7.2%, reflecting steady growth as the focus on infection control and patient safety intensifies. In contrast, the Asia Pacific region is witnessing rapid growth, driven by increasing healthcare investments and rising awareness of antimicrobial resistance, expected to showcase a CAGR of approximately 9.0% during the forecast period.

Opportunities

The Antimicrobial Susceptibility Testing Instrument market is poised to experience significant growth opportunities driven by the escalating need for rapid and accurate diagnostic solutions in both clinical and research settings. As healthcare providers increasingly recognize the importance of timely susceptibility testing, there is a growing demand for innovative testing methodologies that can deliver results quickly. This trend creates opportunities for companies to develop and commercialize advanced testing instruments that incorporate cutting-edge technologies such as automation, AI, and molecular diagnostics. Additionally, the rising global focus on combating antibiotic resistance presents a unique opportunity for market players to contribute to public health initiatives aimed at improving infection control and treatment protocols. By investing in R&D and collaborating with healthcare institutions, companies can position themselves at the forefront of this dynamic market.

Moreover, the growing interest in personalized medicine and tailored treatment approaches is expected to create further opportunities within the antimicrobial susceptibility testing market. As healthcare systems increasingly prioritize individualized patient care, there is a heightened demand for testing solutions that can accurately assess a patient's specific infection profile and susceptibility patterns. This shift paves the way for the development of advanced testing platforms that integrate genomic and phenotypic data to guide treatment decisions. Additionally, emerging markets in regions such as Asia Pacific and Latin America present untapped potential for growth, as healthcare infrastructure continues to improve and access to advanced diagnostic technologies expands. By strategically targeting these emerging markets, companies can capitalize on the increasing demand for accurate susceptibility testing, thereby driving market expansion.

Threats

Despite the promising growth prospects in the Antimicrobial Susceptibility Testing Instrument market, several threats could hinder its expansion. One of the most significant threats is the rapid evolution of antibiotic resistance, which poses challenges for existing testing methodologies. As bacteria evolve and adapt, there is a risk that current testing practices may not adequately reflect the efficacy of available antimicrobial agents, leading to potential misdiagnoses and ineffective treatment plans. This adaptive nature of pathogens necessitates constant innovation and the development of new testing methodologies to keep pace with emerging resistance patterns. Additionally, the high costs associated with advanced testing technologies may limit accessibility in resource-limited settings, hindering the widespread adoption of effective susceptibility testing solutions.

Another potential threat to the market is the stringent regulatory environment governing antimicrobial susceptibility testing. Companies may face delays in product development and approval due to complex regulatory requirements, which can impede the timely introduction of innovative testing solutions to the market. Furthermore, competition among key players in the market is intensifying, with many companies vying for market share through aggressive pricing strategies and product differentiation. This competitive landscape could lead to price wars that may adversely affect profit margins and overall market stability. As a result, market participants must navigate these challenges while continuing to innovate and deliver high-quality testing solutions to maintain their competitive edge.

Competitor Outlook

• BD (Becton, Dickinson and Company)
• bioMérieux S.A.
• Thermo Fisher Scientific Inc.
• Beckman Coulter, Inc.
• Hoffmann-La Roche Ltd.
• Siemens Healthineers
• Abbott Laboratories
• Merck KGaA
• Sysmex Corporation
• Danaher Corporation
• Bruker Corporation
• Cepheid, Inc.
• Microbiologics, Inc.
• VITEK (bioMérieux)
• Greiner Bio-One International GmbH
• Nanosphere, Inc.

The competitive landscape of the Antimicrobial Susceptibility Testing Instrument market is characterized by a diverse array of players, ranging from established companies to emerging startups. Major players like BD (Becton, Dickinson and Company) and bioMérieux S.A. are at the forefront of the market, leveraging their extensive experience and technological expertise to develop innovative testing solutions. These companies are investing heavily in research and development to enhance their product offerings and maintain a competitive edge. Furthermore, collaborations with healthcare institutions and academic organizations are becoming increasingly common, enabling these companies to stay ahead of the curve in addressing the evolving challenges posed by antibiotic resistance.

Another prominent player in the market, Thermo Fisher Scientific Inc., is known for its advanced diagnostics solutions and has a comprehensive portfolio of antimicrobial susceptibility testing instruments. The company's commitment to innovation is reflected in its continuous effort to develop rapid testing methodologies that cater to the needs of clinical laboratories. Similarly, Abbott Laboratories is making strides in the market with its cutting-edge technologies that streamline the testing process and improve patient outcomes. As competition intensifies, companies are also focusing on expanding their presence in emerging markets, recognizing the growing demand for effective diagnostic solutions in regions with rising healthcare investments.

As the market evolves, the competitive landscape is expected to witness the emergence of new players and technologies. Startups specializing in innovative testing methodologies and digital health solutions are entering the market, bringing fresh perspectives and approaches to antimicrobial susceptibility testing. These new entrants often prioritize agility and innovation, enabling them to quickly adapt to market demands and customer needs. In summary, the competitive dynamics of the Antimicrobial Susceptibility Testing Instrument market are characterized by ongoing innovation, strategic collaborations, and a commitment to addressing the pressing challenges posed by antibiotic resistance.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Cepheid, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Nanosphere, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Bruker Corporation
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sysmex Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Abbott Laboratories
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Danaher Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Microbiologics, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Siemens Healthineers
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Beckman Coulter, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hoffmann-La Roche Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 bioMérieux S.A.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 VITEK (bioMérieux)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis
  • 5.16 Greiner Bio-One International GmbH
    • 5.16.1 Business Overview
    • 5.16.2 Products & Services
    • 5.16.3 Financials
    • 5.16.4 Recent Developments
    • 5.16.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Antimicrobial Susceptibility Testing Instrument Sales Market, By Method
    • 6.1.1 Disk Diffusion
    • 6.1.2 Broth Dilution
    • 6.1.3 E-test
    • 6.1.4 Automated Systems
  • 6.2 Antimicrobial Susceptibility Testing Instrument Sales Market, By End User
    • 6.2.1 Hospitals
    • 6.2.2 Diagnostic Laboratories
    • 6.2.3 Pharmaceutical & Biotechnology Companies
    • 6.2.4 Research Institutes
  • 6.3 Antimicrobial Susceptibility Testing Instrument Sales Market, By Application
    • 6.3.1 Clinical Diagnostics
    • 6.3.2 Drug Discovery and Development
    • 6.3.3 Epidemiology
  • 6.4 Antimicrobial Susceptibility Testing Instrument Sales Market, By Product Type
    • 6.4.1 Automated AST Instruments
    • 6.4.2 Manual AST Instruments
    • 6.4.3 Semi-Automated AST Instruments

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Antimicrobial Susceptibility Testing Instrument Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Antimicrobial Susceptibility Testing Instrument Sales market is categorized based on

By Product Type

• Automated AST Instruments
• Manual AST Instruments
• Semi-Automated AST Instruments

By Application

• Clinical Diagnostics
• Drug Discovery and Development
• Epidemiology

By End User

• Hospitals
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Research Institutes

By Method

• Disk Diffusion
• Broth Dilution
• E-test
• Automated Systems

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• BD (Becton, Dickinson and Company)
• bioMérieux S.A.
• Thermo Fisher Scientific Inc.
• Beckman Coulter, Inc.
• Hoffmann-La Roche Ltd.
• Siemens Healthineers
• Abbott Laboratories
• Merck KGaA
• Sysmex Corporation
• Danaher Corporation
• Bruker Corporation
• Cepheid, Inc.
• Microbiologics, Inc.
• VITEK (bioMérieux)
• Greiner Bio-One International GmbH
• Nanosphere, Inc.